ASHP therapeutic position statement on antithrombotic therapy in chronic atrial fibrillation

American Journal of Health-System Pharmacy

Volumn 55, Issue 4, 1998, Pages 376-381

  Talbert, R L ^a   Hart, R G ^a  

^a NONE

Author keywords

American Society of Health System Pharmacists; Anticoagulants; Aspirin; Atrial fibrillation; Cerebrovascular disorders; Organizations; Patient education; Pharmacists; Platelet aggregation inhibitors; Protocols; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; PLACEBO; WARFARIN;

ANTICOAGULANT THERAPY; BRAIN HEMORRHAGE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG MONITORING; HEART ATRIUM FIBRILLATION; HUMAN; MEDICAL SOCIETY; ORAL DRUG ADMINISTRATION; PATIENT EDUCATION; PHARMACIST; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SECONDARY PREVENTION; STROKE; THROMBOEMBOLISM;

EID: 0032519642     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/55.4.376     Document Type: Review

References (41)

1. Laupacis A, Albers G, Dalen J et al. Antithrombotic therapy in atrial fibrillation. Chest. 1995; 108(suppl):352S-9S.
2. Feinberg WM, Blackshear JL, Laupacis A et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Arch Intern Med. 1995; 155:469-73.
3. Levine HJ, Pauker SG, Eckman MH. Antithrombotic therapy in valvular heart disease. Chest. 1995; 108(suppl):360S-70S.
4. Stein PD, Alpert JS, Copeland J et al. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 1995; 108(suppl):371S-9S.
5. Wolf PA, Abbot RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991; 22:983-8.
6. Lake RR, Cullen KJ, deKlerk NH et al. Atrial fibrillation in an elderly population. Aust N Z J Med. 1989; 19:321-6.
7. Philips SJ, Whisnant J, O'Fallon WM et al. Prevalence of cardiovascular disease and diabetes in residents of Rochester, Minnesota. Mayo Clin Proc. 1990; 65:344-59.
8. Furberg CD, Psaty BM, Manolio TA et al. Prevalence of atrial fibrillation in elderly subjects: the Cardiovascular Health Study. Am J Cardiol. 1994; 74:238-41,
9. Nelson KM, Talbert RL. Preventing stroke in patients with nonrheumatic atrial fibrillation. Am J Hosp PHarm, 1994; 51:1175-83.
10. Stroke Prevention in Atrial Fibrillation Investigators. The Stroke Prevention in Atrial Fibrillation study: final results. Circulation. 1991; 84:527-39.
11. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994; 154:1449-57.
12. Stroke Prevention in Atrial Fibrillation Investigators. Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation study. J Stroke Cerebrovasc Dis. 1995; 5:147-57.
13. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. Ann Intern Med. 1992; 116:6-12.
14. Hart RG, Talbert RL, Kadri K et al. Warfarin for stroke prevention: a clinical review. Neurologist. 1996; 2:319-41.
15. Laupacis A, Sackett DL, Robert RS. An assessment of clinically useful measurements of the consequences of treatment. N Engl J Med. 1988; 318:1728-33.
16. Petersen P, Boysen G, Godtfredsen J et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation (AFASAK). Lancet. 1989; 1:175-8.
17. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in nonrheumatic atrial fibrillation. N Engl J Med. 1990; 323:1505-11.
18. Connolly SJ, Laupacis A, Gent M et al. for the CAFA Study Co-investigators. Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J Am Coll Cardiol. 1991; 18:349-55.
19. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med. 1992; 327:1406-12.
20. European Atrial Fibrillation Trial Study Group. Secondary prevention in nonrheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet. 1993; 342:1255-62.
21. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: stroke prevention in atrial fibrillation. II Study. Lancet. 1994; 343:687-91.
22. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348:633-8.
23. Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke. 1995; 26:1471-7.
24. Bussey HI, Force RW, Bianco TM et al. Reliance on prothrombin time ratios causes significant errors in anticoagulation therapy. Arch Intern Med. 1992; 152:278-82.
25. Gottleib LK, Salem-Schatz S. Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med. 1994; 154:1945-53.
26. Fihn SD, Callahan CM, Martin DC et al. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med. 1996; 124:970-9.
27. Palareti G, Leali N, Coccheri S et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study. Lancet, 1996; 348:423-8.
28. European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med. 1995; 333:5-10.
29. Hylek EM, Skates SJ, Sheehan MA et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996; 335:540-6.
30. Miller VT, Rothrock JF, Pearce LA et al. Ischemic stroke in patients with atrial fibrillation: effect of aspirin according to stroke mechanism. Neurology. 1993; 43:32-6.
31. Eckman MH, Levine HJ, Pauker SG. Making decisions about antithrombotic therapy in heart disease. Decision analytic and cost-effectiveness issues. Chest. 1995; 108(suppl):457S-70S.
32. Gage BF, Cardinalli AB, Albers GW et al. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA. 1995; 274:1839-45.
33. Kan BD. Cost effectiveness of stroke prophylaxis for nonvalvular atrial fibrillation. JAMA. 1996; 275:909.
34. Gustafsson C, Asplund K, Britton M et al. Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. BMJ. 1992; 305:1457-60.
35. Hirsh J, Dalen JE, Deykin D et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 1995; 108(suppl):231S-46S.
36. American Society of Health-System Pharmacists. ASHP therapeutic position statement on the use of the International Normalized Ratio system to monitor oral anticoagulant therapy. Am J Health-Syst Pharm. 1995; 52:529-31.
37. Conte RR, Kehoe WA, Nielson N et al. Nine-year experience with a pharmacist-managed anticoagulation clinic. Am J Hosp Pharm. 1986; 43:2460-4.
38. Ansell JE, Hughes R. Evolving models of warfarin management: anticoagulation clinics, patient self-monitoring, and patient self-management. Am Heart J. 1996; 132:1095-100.
39. Radley AS, Hall J, Farrow M et al. Evaluation of anticoagulant control in a pharmacist operated anticoagulant clinic. J Clin Pathol. 1995; 48:545-7.
40. Wilt VM, Gums JG, Ahmed OI et al. Outcome analysis of a pharmacist-managed anticoagulation service. Pharmacotherapy. 1995; 15:732-9.
41. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with routine medical care. Circulation. 1995; 92(suppl 8):I-686.